Related Experiment Video
Updated: Jun 17, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
[Evaluation of serum adiponectin levels in patients with heart failure and relationship with functional capacity]
Mehmet Oztürk1, Dursun Dursunoğlu, Hidayet Göksoy
1Department of Cardiology, Medicine Faculty of Pamukkale University, Denizli, Turkey.
Insights
Serum adiponectin levels increase with worsening heart failure (HF) functional capacity. Higher adiponectin correlates with reduced ejection fraction (EF) in HF patients.
Area of Science:
- Cardiology
- Biochemistry
- Internal Medicine
Context:
- Heart failure (HF) is a complex clinical syndrome.
- Assessing HF severity and progression is crucial for patient management.
- Adiponectin, an adipokine, has been implicated in cardiovascular disease.
Purpose:
- To investigate the relationship between serum adiponectin levels and the New York Heart Association (NYHA) functional capacity classification in patients with heart failure.
- To compare adiponectin levels and echocardiographic parameters between HF patients and a control group.
Summary:
- This study included 49 HF patients (NYHA class II-IV) and 41 controls.
- HF patients had higher adiponectin levels and lower ejection fraction (EF) compared to controls.
- Serum adiponectin levels significantly increased with NYHA class (II to IV) and inversely correlated with EF.
Impact:
- Serum adiponectin may serve as a biomarker for HF severity and progression.
- Findings highlight the role of adiponectin in the pathophysiology of heart failure.
- This research contributes to understanding the metabolic derangements in heart failure.
Objectives:
We aimed to evaluate serum adiponectin levels in relation to the NYHA functional capacity class in patients with heart failure (HF).
Study Design:
The study included 49 patients (40 males, 9 females; mean age 63 years) with HF, whose functional capacity was NYHA class II to IV. Echocardiographic examination was performed and serum adiponectin levels were measured. The results were compared in relation to the NYHA classes and with those of 41 control subjects (24 males, 17 females; mean age 54.2 years) without HF.
Results:
Functional capacity was NYHA class II in 13 patients (26.5%), class III in 23 patients (46.9%), and class IV in 13 patients (26.5%). Compared to the control group, the HF group exhibited a significantly higher mean age (p=0.001), lower body mass index (p=0.004), decreased left ventricular ejection fraction (EF) (33.2+/-7.7% vs. 64.9+/-4.3%; p=0.0001), and increased serum adiponectin level (4.0+/-3.2 micromg/dl vs. 2.4+/-2.3 micromg/dl; p=0.009). Both EF (p=0.001) and adiponectin level (p=0.004) showed significant differences between the NYHA groups, with the latter showing a sharp increase from 2.6+/-2.6 micromg/dl in class II to 6.8+/-3.7 micromg/dl in class IV. In all paired comparisons between the three NYHA groups, EF and serum adiponectin level exhibited significant differences except for the serum adiponectin level for NYHA class II and III (for NYHA class II and IV, p=0.003; for class III and IV, p=0.008). In correlation analysis, serum adiponectin level was in a significantly inverse correlation with EF (r=-0.380, p=0.0001), and a positive correlation with the NYHA class (r=0.423, p=0.0001).
Conclusion:
Serum adiponectin levels significantly increase in patients with HF, in parallel with deterioration in functional capacity and with significant decreases in EF.
Related Concept Videos
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure VII: Nursing Interventions
Heart Failure VI: Adjunct Therapies
Heart Failure II: Pathophysiology
Heart Failure III: Clinical Manifestations
Pathophysiology of Heart Failure